Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

Thomas PJ Garrett; Anthony W Burgess; Hui K Gan; Rodney B Luwor; Glenn A Cartwright; Francesca Walker; Suzanne G Orchard; Andrew H A Clayton; Edouard C Nice; Julie Rothacker; Bruno Catimel; Webster K Cavenee; Lloyd J Old; Elisabeth Stockert; Gerd Ritter; Timothy E Adams; Peter A Hoyne; Dane Dane Wittrup; Ginger Chao; Jennifer R Cochran; Cindy S Luo; Mezhen Lou; Trevor Huyton; Yibin Xu; W Douglas Fairlie; Shenggen Yao; Andrew M Scott; Terrance Grant Johns

doi:10.1073/pnas.0811559106

Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

Thomas PJ Garrett, Anthony W Burgess, Hui K Gan, Rodney B Luwor, Glenn A Cartwright, Francesca Walker, Suzanne G Orchard, Andrew H A Clayton, Edouard C Nice, Julie Rothacker, Bruno Catimel, Webster K Cavenee, Lloyd J Old, Elisabeth Stockert, Gerd Ritter, Timothy E Adams, Peter A Hoyne, Dane Dane Wittrup, Ginger Chao, Jennifer R CochranCindy S Luo, Mezhen Lou, Trevor Huyton, Yibin Xu, W Douglas Fairlie, Shenggen Yao, Andrew M Scott, Terrance Grant Johns

Hudson Institute - Centre for Cancer Research

Research output: Contribution to journal › Article › Research › peer-review

71 Citations (Scopus)

Abstract

Abstract Monoclonal antibodies (mAb s) and tyrosine kinase inhibitors targeting the Epidermal Growth Factor receptor (EGFR), which is often pathogenetically (over-)expressed or mutated in epithelial malignancies and glioma, have been modestly successful, with some approved for human use. MAb 806 was raised against de2-7EGFR (or EGFRvIII), a constitutively active mutation expressed in gliomas, but also recognizes a subset (

Original language	English
Pages (from-to)	5082 - 5087
Number of pages	6
Journal	Proceedings of the National Academy of Sciences of the United States of America
Volume	106
Issue number	13
DOIs	https://doi.org/10.1073/pnas.0811559106
Publication status	Published - 2009

Access to Document

10.1073/pnas.0811559106

Cite this

Garrett, T. PJ., Burgess, A. W., Gan, H. K., Luwor, R. B., Cartwright, G. A., Walker, F., Orchard, S. G., Clayton, A. H. A., Nice, E. C., Rothacker, J., Catimel, B., Cavenee, W. K., Old, L. J., Stockert, E., Ritter, G., Adams, T. E., Hoyne, P. A., Wittrup, D. D., Chao, G., ... Johns, T. G. (2009). Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proceedings of the National Academy of Sciences of the United States of America, 106(13), 5082 - 5087. https://doi.org/10.1073/pnas.0811559106

@article{6b77a75adcf544b8aed1266bb95624cc,

title = "Antibodies specifically targeting a locally misfolded region of tumor associated EGFR",

abstract = "Abstract Monoclonal antibodies (mAb s) and tyrosine kinase inhibitors targeting the Epidermal Growth Factor receptor (EGFR), which is often pathogenetically (over-)expressed or mutated in epithelial malignancies and glioma, have been modestly successful, with some approved for human use. MAb 806 was raised against de2-7EGFR (or EGFRvIII), a constitutively active mutation expressed in gliomas, but also recognizes a subset (",

author = "Garrett, \{Thomas PJ\} and Burgess, \{Anthony W\} and Gan, \{Hui K\} and Luwor, \{Rodney B\} and Cartwright, \{Glenn A\} and Francesca Walker and Orchard, \{Suzanne G\} and Clayton, \{Andrew H A\} and Nice, \{Edouard C\} and Julie Rothacker and Bruno Catimel and Cavenee, \{Webster K\} and Old, \{Lloyd J\} and Elisabeth Stockert and Gerd Ritter and Adams, \{Timothy E\} and Hoyne, \{Peter A\} and Wittrup, \{Dane Dane\} and Ginger Chao and Cochran, \{Jennifer R\} and Luo, \{Cindy S\} and Mezhen Lou and Trevor Huyton and Yibin Xu and Fairlie, \{W Douglas\} and Shenggen Yao and Scott, \{Andrew M\} and Johns, \{Terrance Grant\}",

year = "2009",

doi = "10.1073/pnas.0811559106",

language = "English",

volume = "106",

pages = "5082 -- 5087",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

publisher = "National Academy of Sciences",

number = "13",

}

Garrett, TPJ, Burgess, AW, Gan, HK, Luwor, RB, Cartwright, GA, Walker, F, Orchard, SG, Clayton, AHA, Nice, EC, Rothacker, J, Catimel, B, Cavenee, WK, Old, LJ, Stockert, E, Ritter, G, Adams, TE, Hoyne, PA, Wittrup, DD, Chao, G, Cochran, JR, Luo, CS, Lou, M, Huyton, T, Xu, Y, Fairlie, WD, Yao, S, Scott, AM & Johns, TG 2009, 'Antibodies specifically targeting a locally misfolded region of tumor associated EGFR', Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 13, pp. 5082 - 5087. https://doi.org/10.1073/pnas.0811559106

TY - JOUR

T1 - Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

AU - Garrett, Thomas PJ

AU - Burgess, Anthony W

AU - Gan, Hui K

AU - Luwor, Rodney B

AU - Cartwright, Glenn A

AU - Walker, Francesca

AU - Orchard, Suzanne G

AU - Clayton, Andrew H A

AU - Nice, Edouard C

AU - Rothacker, Julie

AU - Catimel, Bruno

AU - Cavenee, Webster K

AU - Old, Lloyd J

AU - Stockert, Elisabeth

AU - Ritter, Gerd

AU - Adams, Timothy E

AU - Hoyne, Peter A

AU - Wittrup, Dane Dane

AU - Chao, Ginger

AU - Cochran, Jennifer R

AU - Luo, Cindy S

AU - Lou, Mezhen

AU - Huyton, Trevor

AU - Xu, Yibin

AU - Fairlie, W Douglas

AU - Yao, Shenggen

AU - Scott, Andrew M

AU - Johns, Terrance Grant

PY - 2009

Y1 - 2009

N2 - Abstract Monoclonal antibodies (mAb s) and tyrosine kinase inhibitors targeting the Epidermal Growth Factor receptor (EGFR), which is often pathogenetically (over-)expressed or mutated in epithelial malignancies and glioma, have been modestly successful, with some approved for human use. MAb 806 was raised against de2-7EGFR (or EGFRvIII), a constitutively active mutation expressed in gliomas, but also recognizes a subset (

AB - Abstract Monoclonal antibodies (mAb s) and tyrosine kinase inhibitors targeting the Epidermal Growth Factor receptor (EGFR), which is often pathogenetically (over-)expressed or mutated in epithelial malignancies and glioma, have been modestly successful, with some approved for human use. MAb 806 was raised against de2-7EGFR (or EGFRvIII), a constitutively active mutation expressed in gliomas, but also recognizes a subset (

UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656555/pdf/zpq5082.pdf

UR - https://www.scopus.com/pages/publications/65249179550

U2 - 10.1073/pnas.0811559106

DO - 10.1073/pnas.0811559106

M3 - Article

SN - 0027-8424

VL - 106

SP - 5082

EP - 5087

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

IS - 13

ER -

Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

Abstract

Access to Document

Other files and links

Cite this